Literature DB >> 8593732

The physiology of pre-eclampsia.

M A Brown1.   

Abstract

1. Pre-eclampsia is a multisystem disorder of human pregnancy with a genetic predisposition. It occurs more commonly in first pregnancies and primarily affects maternal renal, cerebral, hepatic and clotting functions while elevating blood pressure. The foetus is affected through placental insufficiency arising from abnormal 'placentation', that is, failure to adequate trophoblast invasion of maternal vasculature, and possible from abnormal autacoid production. 2. Pre-eclampsia is caused by the placenta; delivery of the placenta is the only known cure. Its manifestations are considered secondary to organ hypoperfusion which arises as a result of vasoconstriction, intravascular coagulation and reduced maternal blood volume. 3. Current hypotheses propose that pre-eclampsia is due to widespread maternal endothelial cell damage, perhaps secondary to a cytotoxic factor released by the placenta. This hypothesis has gained wide acceptance, but scientific evidence is lacking. 4. Defining the abnormal balance of vasoactive factors in pre-eclampsia has proved a difficult task. There is enhanced pressor activity to infused angiotensin II (AII) despite reduced plasma concentrations of AII, renin and aldosterone. Prostacyclin production appears reduced, and the balance of thromboxane/prostacyclin favours vasoconstriction and platelet aggregation. There is no convincing evidence for enhanced endothelin or reduced nitric oxide production. Plasma concentrations of atrial natriuretic peptide are paradoxically elevated in the face of plasma volume contraction. An intriguing observation, which remains unexplained, is why some vascular beds are affected predominantly in one patient (eg. hepatic ischaemia) while another has a similar degree of hypertension but involvement of a different organ system (eg. renal insufficiency yet normal liver function). 5. Volume homeostasis is disturbed with redistribution of intravascular volume to the interstitial fluid space due to increased capillary permeability and in some cases reduced plasma oncotic pressure. This redistribution is not always clinically apparent as peripheral oedema. Whether this change in volume is compensated for by venoconstriction and maintenance of adequate cardiac output is undetermined. 6. Improved understanding of the pathophysiology of pre-eclampsia is necessary to allow better clinical management of this serious disorder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593732     DOI: 10.1111/j.1440-1681.1995.tb01937.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  22 in total

Review 1.  Sleep Disordered Breathing, a Novel, Modifiable Risk Factor for Hypertensive Disorders of Pregnancy.

Authors:  Laura Sanapo; Margaret H Bublitz; Ghada Bourjeily
Journal:  Curr Hypertens Rep       Date:  2020-03-12       Impact factor: 5.369

2.  Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2.

Authors:  D W Thomas; R B Mannon; P J Mannon; A Latour; J A Oliver; M Hoffman; O Smithies; B H Koller; T M Coffman
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

3.  Mechanisms of enhanced vascular reactivity in preeclampsia.

Authors:  Nikita Mishra; William H Nugent; Sunila Mahavadi; Scott W Walsh
Journal:  Hypertension       Date:  2011-09-26       Impact factor: 10.190

Review 4.  The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.

Authors:  Marilyn J Cipolla; David S Liebeskind; Siu-Lung Chan
Journal:  J Cereb Blood Flow Metab       Date:  2018-09-10       Impact factor: 6.200

5.  Change in brain size during and after pregnancy: study in healthy women and women with preeclampsia.

Authors:  Angela Oatridge; Anita Holdcroft; Nadeem Saeed; Joseph V Hajnal; Basant K Puri; Luca Fusi; Graeme M Bydder
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

6.  Uric acid induces trophoblast IL-1β production via the inflammasome: implications for the pathogenesis of preeclampsia.

Authors:  Melissa J Mulla; Kledia Myrtolli; Julie Potter; Crina Boeras; Paula B Kavathas; Anna K Sfakianaki; Serkelem Tadesse; Errol R Norwitz; Seth Guller; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2011-06       Impact factor: 3.886

7.  Integration of metabolomic and transcriptomic networks in pregnant women reveals biological pathways and predictive signatures associated with preeclampsia.

Authors:  Rachel S Kelly; Damien C Croteau-Chonka; Amber Dahlin; Hooman Mirzakhani; Ann C Wu; Emily S Wan; Michael J McGeachie; Weiliang Qiu; Joanne E Sordillo; Amal Al-Garawi; Kathryn J Gray; Thomas F McElrath; Vincent J Carey; Clary B Clish; Augusto A Litonjua; Scott T Weiss; Jessica A Lasky-Su
Journal:  Metabolomics       Date:  2016-12-12       Impact factor: 4.290

Review 8.  Preeclampsia-eclampsia.

Authors:  Sanjay Gupte; Girija Wagh
Journal:  J Obstet Gynaecol India       Date:  2014-01-31

9.  Vascular endothelial growth factor acts through novel, pregnancy-enhanced receptor signalling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells.

Authors:  Mary A Grummer; Jeremy A Sullivan; Ronald R Magness; Ian M Bird
Journal:  Biochem J       Date:  2009-01-15       Impact factor: 3.857

10.  Is human placenta proteoglycan remodeling involved in pre-eclampsia?

Authors:  Mohamad Warda; Fuming Zhang; Moustafa Radwan; Zhenqing Zhang; Nari Kim; Young Nam Kim; Robert J Linhardt; Jin Han
Journal:  Glycoconj J       Date:  2007-12-27       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.